Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. has a portfolio in the Biotechnology & Pharmaceuticals technology area. The data shows 1 pending office action for the company. This specific level of activity suggests a focused approach to the company's current intellectual property development and patent office engagement.
The prosecution of these assets is concentrated, involving 1 distinct examiner and 1 distinct art unit. This arrangement indicates that the company's current legal efforts are directed toward a specific technical field. Practitioners can observe that the strategy avoids the complexities associated with managing filings across various examination divisions.
The busiest examiner for the portfolio is STONEBRAKER, ALYSSA RAE, who is assigned 1 busiest examiner pending office action. This 1 busiest examiner pending office action represents the total 1 pending office action currently active for the company. This alignment means that the immediate progress of the portfolio is subject to the review of this specific examiner.
Success in the 1 distinct art unit will be the key indicator of the portfolio's overall direction. Since all current prosecution is centralized, the examiner's specific requirements and the art unit's internal standards are critical factors for the company. This environment provides the clear path for tracking the status of the pending application.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STONEBRAKER, ALYSSA RAE | 1 | 58.3% | +49.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17622500 | ANTIBODY-DRUG CONJUGATE, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | STONEBRAKER, ALYSSA RAE | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17622500 | ANTIBODY-DRUG CONJUGATE, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | STONEBRAKER, ALYSSA RAE | 1642 | §103§112DP | Non-Final OA | — | Pending | Dec 23, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial